Business Segments · Acquired in-process research and development
Business Segments — Acquired in-process research and development
Neurocrine Biosciences Business Segments — Acquired in-process research and development increased by 24.7% to $21.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21100.0%, from $100.00K to $21.20M.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toAcquired in-process research and development
How to read this metric
High values indicate active business development and strategic expansion of the drug pipeline.
Detailed definition
Reflects the costs associated with acquiring intellectual property or clinical-stage assets from third parties. This rep...
Peer comparison
Common in biotech; varies significantly based on the timing of acquisitions and licensing deals.
Metric ID:
nbix_segment_reportable_segment_acquired_in_process_research_and_developmentHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $35.98M | $35.98M | $35.98M | $35.98M | $6.00M | $2.50M | $1.00M | $3.00M | $100.00K | $0.00 | $300.00K | $17.00M | $21.20M |
| QoQ Change | — | — | — | — | — | +0.0% | +0.0% | +0.0% | -83.3% | -58.3% | -60.0% | +200.0% | -96.7% | -100.0% | — | >999% | +24.7% |
| YoY Change | — | — | — | — | — | — | — | — | -83.3% | -93.1% | -97.2% | -91.7% | -98.3% | -100.0% | -70.0% | +466.7% | >999% |
Range$0.00 – $35.98M
Avg YoY Growth>999%
Median YoY Growth-91.7%
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's business segments — acquired in-process research and development?
- Neurocrine Biosciences (NBIX) reported business segments — acquired in-process research and development of $21.20M in Q1 2026.
- How has Neurocrine Biosciences's business segments — acquired in-process research and development changed year-over-year?
- Neurocrine Biosciences's business segments — acquired in-process research and development increased by 21100.0% year-over-year, from $100.00K to $21.20M.
- What does business segments — acquired in-process research and development mean?
- Costs incurred to purchase research projects or drug candidates from other companies.